[go: up one dir, main page]

AR070752A1 - Compuestos activos como antagonistas de receptores muscarinicos, composiciones farmaceuticas que lo contienen, uso de dichos compuestos para la manufactura de un farmaco, combinacion de dichos compuestos con otros agentes terapeuticos, y procedimiento para la preparacion de dichos compuestos - Google Patents

Compuestos activos como antagonistas de receptores muscarinicos, composiciones farmaceuticas que lo contienen, uso de dichos compuestos para la manufactura de un farmaco, combinacion de dichos compuestos con otros agentes terapeuticos, y procedimiento para la preparacion de dichos compuestos

Info

Publication number
AR070752A1
AR070752A1 ARP080103992A ARP080103992A AR070752A1 AR 070752 A1 AR070752 A1 AR 070752A1 AR P080103992 A ARP080103992 A AR P080103992A AR P080103992 A ARP080103992 A AR P080103992A AR 070752 A1 AR070752 A1 AR 070752A1
Authority
AR
Argentina
Prior art keywords
asthma
inhibitors
bronchitis
antagonists
bronchiectasis
Prior art date
Application number
ARP080103992A
Other languages
English (en)
Inventor
Charlotte Alice Louise Lane
Paul Alan Glossop
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AR070752A1 publication Critical patent/AR070752A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/21—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque es de formula (1) en la que R1 es H o alquilo C1-4; R2 es alquilo C1C4 o un grupo -X-R3; X es un enlace, -CH2-, -SO2-, -C(=O)- o -C(=O)-CH2-; R3 es cicloalquilo C3-10, formándose opcionalmente un puente entre 2 átomos de carbono o más de dicho cicloalquilo mediante uno o más átomos de carbono, o arilo, estando sustituidos opcionalmente dichos cicloalquilo y arilo con 1, 2 o 3 grupos seleccionados independientemente de hidroxilo, halogeno, ciano, alquilo C1-4, O-alquilo C1-4 o S-alquilo C1-4; o una sal o un solvato farmacéuticamente aceptable del mismo. Reivindicacion 10: Una composicion farmacéutica caracterizada porque comprende al menos una cantidad eficaz de un compuesto de formula (1) segun lo descrito en una cualquiera de las reivindicaciones 1 a 9 o una sal o un solvato farmacéuticamente aceptable del mismo. Reivindicacion 12: El uso de un compuesto de formula (1) segun lo descrito en una cualquiera de las reivindicaciones 1 a 9, o una sal o un solvato farmacéuticamente aceptable del mismo, caracterizado porque es para la fabricacion de un fármaco para el tratamiento de enfermedades, trastornos y afecciones seleccionadas del grupo que está constituido por broncoconstriccion cronica o aguda, bronquitis cronica, obstruccion de las vías respiratorias pequenas y enfisema, enfermedades de las vías respiratorias obstructivas o inflamatorias de cualquier tipo, etiología o patogénesis, en particular una enfermedad de las vías respiratorias obstructiva o inflamatoria que es un miembro seleccionado del grupo que está constituido por neumonía eosinofila cronica, enfermedad pulmonar obstructiva cronica (EPOC), EPOC que incluye bronquitis cronica, enfisema pulmonar o disnea asociada o no asociada a EPOC, EPOC que se caracteriza por obstruccion de las vías respiratorias progresiva, irreversible, síndrome del distrés respiratorio en el adulto (SDRA), exacerbacion de la hiperreactividad de las vías respiratorias consiguiente a otra terapia farmacologica y enfermedad de las vías respiratorias que está asociada a hipertension pulmonar, bronquitis de cualquier tipo, etiología o patogénesis, en particular bronquitis que es un miembro seleccionado del grupo que está constituido por bronquitis aguda, bronquitis laringotraqueal aguda, bronquitis araquídica, bronquitis catarral, bronquitis seudomembranosa, bronquitis seca, bronquitis asmática infecciosa, bronquitis productiva, bronquitis estafilococica o estreptococica y bronquitis vesicular, asma de cualquier tipo, etiología o patogénesis, en particular asma que es un miembro seleccionado del grupo que está constituido por asma atopica, asma no atopica, asma alérgica, asma bronquial atopica mediada por IgE, asma bronquial, asma esencial, asma verdadera, asma intrínseca provocada por alteraciones patofisiologicas, asma extrínseca provocada por factores medioambientales, asma esencial de causa desconocida o no aparente, asma no atopica, asma bronquítica, asma enfisematosa, asma inducida por ejercicio, asma inducida por alérgenos, asma inducida por aire frío, asma ocupacional, asma infecciosa provocada por infeccion bacteriana, fungica, protozoárica o viral, asma no alérgica, asma incipiente, síndrome de estertor en lactantes y bronquiolitis, lesion pulmonar aguda, bronquiectasia de cualquier tipo, etiología o patogénesis, en particular bronquiectasia que es un miembro seleccionado del grupo que está constituido por bronquiectasia cilíndrica, bronquiectasia sacular, bronquiectasia fusiforme, bronquiectasia capilar, bronquiectasia quística, bronquiectasia seca y bronquiectasia folicular. Reivindicacion 13: Combinacion de un compuesto segun una cualquiera de ?as reivindicaciones 1 a 9, o una sal o un solvato farmacéuticamente aceptable del mismo! con otro(s) agente(s) terapéutico(s) seleccionado(s) de: (a) inhibidores de la 5-lipoxigenasa (5-LO) o antagonistas de la proteína activadora de la 5-lipoxigenasa (FLAP), (b) antagonistas de leucotrienos (LTRA) incluyendo antagonistas de LTB4, LTC4, LTD4 y LTE4, (c) antagonistas de receptores de histamina incluyendo antagonistas de H1 y H3, (d) agentes simpaticomiméticos vasoconstrictores agonistas del adrenorreceptor alfa1 y alfa2 para uso descongestionante, (e) inhibidores de PDE, por ejemplo inhibidores de PDE3, PDE4 y PDE5, (f) agonistas de receptores beta 2, (g) compuestos dobles activos como agonistas de beta2 y antagonistas de receptores M3 muscarínicos, (h) teofilina, (i) cromoglicato de sodio, (j) inhibidores de COX, inhibidores de COX-1 o COX-2 ambos selectivos y no selectivos (AINE), (k) antagonistas de receptores de prostaglandinas e inhibidores de prostaglandina sintasa, (l) glucocorticosteroides orales e inhalados, tales como agonistas disociados del receptor de corticoides (DAGR); (m) anticuerpos monoclonales activos contra entidades inflamatorias endogenas, (n) agentes contra el factor de necrosis tumoral (anti-TNF-alfa), (o) inhibidores de moléculas de adhesion incluyendo antagonistas de VLA-4, (p) antagonistas dé receptores B1 y B2 de kinina, (q) agentes inmunosupresores, incluyendo inhibidores de la ruta de IgE y ciclosporina, (r) inhibidores de metaloproteasas de la matriz (MMP), (s) antagonistas de receptores NK1, NK2 y NK3 de taquikinina, (t) inhibidores de proteasas tales como inhibidores de elastasas, (u) agonistas de receptores A2a de adenosina y antagonistas de A2b, (v) inhibidores de la uroquinasa, (w) compuestos que actuan sobre receptores de dopamina, tales como agonistas de D2, (x) moduladores de la ruta de NFkB, tales como inhibidores de IKK, (y) moduladores de las rutas de senalizacion de citocinas tales como MAP quinasa p38, quinasa PI3, JAK quinasa, syk quinasa, EGFR o MK-2, (z) agentes que pueden clasificarse como mucolíticos o antitusivos, (aa) agentes que potencian respuestas frente a corticosteroides inhalados, (bb) antibioticos y agentes antivirales eficaces contra microorganismos que pueden colonizar el tracto respiratorio, (cc) inhibidores de HDAC, (dd) antagonistas de CXCR2, (ee) antagonistas de integrina, (ff) quimiocinas, (gg) bloqueadores del canal de sodio epitelial (ENaC) o inhibidores del canal de sodio epitelial (ENaC), (hh) agonistas de P2Y2 y otros agonistas de receptores de nucleotidos, (ii) inhibidores de tromboxano, (jj) inhibidores de la síntesis de PGD2 y receptores de PGD2 (DP1 y DP2/GRTH2); (kk) niacina, y (II) factores de adhesion incluyendo VLAM, ICAM y ELAM. Reivindicacion 14: Un procedimiento para la preparacion de un compuesto de formula (1) en la que R1 y R2 son segun se definen en la reivindicacion 1, caracterizado porque comprende dicho procedimiento la etapa de hacer reaccionar un compuesto de formula (2) en la que Rd es H o Rc en la que Rc es un grupo protector adecuado, con un ácido carboxílico de formula R3CO2H o R3CH3-CO2H, un cloruro de sulfonilo de formula R3SO2CI o aldehídos/cetonas de formula R3C(=O)H y R3=O.
ARP080103992A 2007-09-14 2008-09-12 Compuestos activos como antagonistas de receptores muscarinicos, composiciones farmaceuticas que lo contienen, uso de dichos compuestos para la manufactura de un farmaco, combinacion de dichos compuestos con otros agentes terapeuticos, y procedimiento para la preparacion de dichos compuestos AR070752A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97228207P 2007-09-14 2007-09-14

Publications (1)

Publication Number Publication Date
AR070752A1 true AR070752A1 (es) 2010-05-05

Family

ID=40257316

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103992A AR070752A1 (es) 2007-09-14 2008-09-12 Compuestos activos como antagonistas de receptores muscarinicos, composiciones farmaceuticas que lo contienen, uso de dichos compuestos para la manufactura de un farmaco, combinacion de dichos compuestos con otros agentes terapeuticos, y procedimiento para la preparacion de dichos compuestos

Country Status (12)

Country Link
US (1) US20090076152A1 (es)
EP (1) EP2200969A2 (es)
JP (1) JP2010539154A (es)
AR (1) AR070752A1 (es)
CA (1) CA2699463A1 (es)
CL (1) CL2008002696A1 (es)
HN (1) HN2008001435A (es)
PA (1) PA8795901A1 (es)
PE (1) PE20091272A1 (es)
TW (1) TW200922545A (es)
UY (1) UY31338A1 (es)
WO (1) WO2009034432A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
CN105044263B (zh) * 2015-07-09 2017-01-04 蚌埠中实化学技术有限公司 一种4-乙氧基-2,3-二氟苯酚的气相色谱检验方法
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US20230293430A1 (en) 2020-06-26 2023-09-21 Mylan Pharma Uk Limited Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020547A1 (es) * 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
EA016203B1 (ru) * 2006-03-20 2012-03-30 Пфайзер Лимитед Производные амина

Also Published As

Publication number Publication date
WO2009034432A3 (en) 2009-05-22
CL2008002696A1 (es) 2009-11-13
PE20091272A1 (es) 2009-09-18
JP2010539154A (ja) 2010-12-16
WO2009034432A8 (en) 2010-03-11
TW200922545A (en) 2009-06-01
HN2008001435A (es) 2010-10-04
UY31338A1 (es) 2009-04-30
US20090076152A1 (en) 2009-03-19
EP2200969A2 (en) 2010-06-30
PA8795901A1 (es) 2009-04-23
WO2009034432A2 (en) 2009-03-19
CA2699463A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
US10745473B2 (en) Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
AR070752A1 (es) Compuestos activos como antagonistas de receptores muscarinicos, composiciones farmaceuticas que lo contienen, uso de dichos compuestos para la manufactura de un farmaco, combinacion de dichos compuestos con otros agentes terapeuticos, y procedimiento para la preparacion de dichos compuestos
JP2009530364A5 (es)
EP2244574B1 (en) Tricyclic compounds as modulators of tnf- synthesis and as pde4 inhibitors
AU2016320748B2 (en) Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
JP5032990B2 (ja) 結晶性形態のビフェニル化合物
ES2345640T3 (es) Compuestos de bifenilo utiles en la sintesis de antagonistas del receptor muscarinico.
CA2706180A1 (en) Novel glucocorticoid receptor agonists
ES2329133T3 (es) Compuestos azabicicloalcanicos como antagonistas de receptores de muscarinicos.
ES2397209T3 (es) Sal mesilato de5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexi)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1H)-ona como agonista del receptor b2 adrenérgico
ES2353549T3 (es) Quinolonas sustituidas y métodos de uso.
CN101379057B (zh) 联苯-2-基氨基甲酸1-[2-(2-氯-4-{[(r)-2-羟基-2-(8-羟基-2-氧代-1,2-二氢喹啉-5-基)乙基氨基]甲基}-5-甲氧基苯基氨甲酰基)乙基]哌啶-4-基酯的琥珀酸盐及其治疗肺疾病的用途
CA2643097A1 (en) Amine derivatives
TW201900170A (zh) 使用jak抑制劑化合物之治療方法
EP3725785B1 (en) Glutarimide derivative, use thereof, pharmaceutical composition based thereon and methods for producing the glutarimide derivative
AU2004229527A1 (en) Methods of preventing or treating respiratory conditions
CN103140485B (zh) 二酰胺化合物的结晶草酸盐
JP2010510268A (ja) Ｃｘｃｒ２アンタゴニストとしての５−スルファニルメチル−［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−７−オール
CA2678683A1 (en) Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
PT509398E (pt) Quinoxalinas processo para a sua preparacao e sua utilizacao
CA2623332A1 (en) Carboxamide derivatives as muscarinic receptor antagonists
JP2007528415A (ja) ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
ES2351392T3 (es) Derivados bifenilo que tienen actividad agonista de receptores beta2-adrenérgicos y actividad antagonista de receptores muscarínicos.
JP2018534324A (ja) 上皮バリア機能増強特性を有するアジスロマイシン誘導体
CA2667566A1 (en) Pyrazole analogs

Legal Events

Date Code Title Description
FB Suspension of granting procedure